Cardiff Oncology, Inc. Common Stock CRDF
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-11T14:44:24.248Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T14:40:00.121967725Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-11T14:41:19.983738+00:00
Cardiff Oncology, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | ||||||
| 40Δ | ||||||
| 45Δ | ||||||
| 50Δ | 0.78 | 315.7% | 21.2% | 1.04 | 458.5% | 19.8% |
| 55Δ | 0.74 | 343.0% | 19.6% | 1.12 | 442.5% | 17.3% |
| 60Δ | 0.69 | 370.4% | 18.0% | 1.20 | 426.4% | 14.8% |
| 65Δ | 0.65 | 397.7% | 16.5% | 1.28 | 410.4% | 12.2% |
| 70Δ | 0.61 | 425.0% | 14.9% | 1.36 | 394.3% | 9.7% |
| 75Δ | 0.57 | 452.4% | 13.3% | 1.44 | 378.3% | 7.2% |
| 80Δ | 0.53 | 479.7% | 11.8% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- 0.78
- IV
- 315.7%
- B/E move
- 21.2%
- Pseudo strike
- 1.04
- IV
- 458.5%
- B/E move
- 19.8%
55Δ
- Pseudo strike
- 0.74
- IV
- 343.0%
- B/E move
- 19.6%
- Pseudo strike
- 1.12
- IV
- 442.5%
- B/E move
- 17.3%
60Δ
- Pseudo strike
- 0.69
- IV
- 370.4%
- B/E move
- 18.0%
- Pseudo strike
- 1.20
- IV
- 426.4%
- B/E move
- 14.8%
65Δ
- Pseudo strike
- 0.65
- IV
- 397.7%
- B/E move
- 16.5%
- Pseudo strike
- 1.28
- IV
- 410.4%
- B/E move
- 12.2%
70Δ
- Pseudo strike
- 0.61
- IV
- 425.0%
- B/E move
- 14.9%
- Pseudo strike
- 1.36
- IV
- 394.3%
- B/E move
- 9.7%
75Δ
- Pseudo strike
- 0.57
- IV
- 452.4%
- B/E move
- 13.3%
- Pseudo strike
- 1.44
- IV
- 378.3%
- B/E move
- 7.2%
80Δ
- Pseudo strike
- 0.53
- IV
- 479.7%
- B/E move
- 11.8%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 234.83% | |
| 341.87% | |
| 239.44% | |
| 336.49% | |
| 261.80% | |
| 307.78% |
Biotechnology
CRMD
CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in…
More →CRSP
CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. The company is headquartered in Zug,…
More →CRVS
Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. The company is…
More →CTMX
Description unavailable
More →CTNM
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation,…
More →CYTK
Cytokinetics, Incorporated, an advanced stage biopharmaceutical company, focuses on discovering, developing and commercializing muscle activators and inhibitors as potential…
More →